Skip to main content
  • Book
  • © 1983

Biological Response Modifiers in Human Oncology and Immunology

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 166)

Buy it now

Buying options

eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (27 chapters)

  1. Front Matter

    Pages i-xiv
  2. Introduction

    1. Immunostimulation in Cancer Patients

      • Yuichi Yamamura, Ichiro Azuma
      Pages 1-13
  3. Biological Response Modifiers Derived from Leukocytes

    1. Interferons: Several Questions and Few Answers

      • William E. Stewart II
      Pages 15-21
    2. Interferon Hybrids: Prospects for Therapy

      • Nowell Stebbing
      Pages 23-35
    3. Monoclonal Antibodies as Anticancer Agents

      • Robert K. Oldham
      Pages 45-57
    4. Treatment of a Murine Leukemia with Chlorambucil Bound Monoclonal Antibodies

      • Burton Feinerman, Ronald D. Paul, Gregg Feinerman
      Pages 59-66
    5. Immune Response in Strain 2 Guinea Pigs to the Syngeneic L2C Leukemia

      • Manuel J. Ricardo Jr., Daniel T. Grimm
      Pages 67-78
    6. Protective Activity of Thymosin α1 Against Tumor Progression in Immunosuppressed Mice

      • Hideo Ishitsuka, Yukio Umeda, Atsuko Sakamoto, Yasuo Yagi
      Pages 89-100
    7. Interleukins in Experimental Autoimmune Disease

      • Norman Talal, Michael Fischbach
      Pages 105-115
  4. Biological Response Modifiers Derived from Microorganisms

    1. Muramyl Dipeptides: Prospect for Cancer Treatments and Immunostimulation

      • Shozo Kotani, Ichiro Azuma, Haruhiko Takada, Masachika Tsujimoto, Yuichi Yamamura
      Pages 117-158
    2. Clinical Phase I Investigation of Intravenous Oil Attached Mycobacterial Components as Immunotherapeutic Agents

      • Gerald Vosika, Tim Trenbeath, Cathy Giddings, Gary R. Gray
      Pages 159-169
    3. Immunomodulating Effects of a Short-Term Oral Treatment with C 1821 in Untreated Cancer Patients: A Controlled Study

      • J. M. Lang, A. Aleksijevic, C. Giron, S. Levy, A. Falkenrodt, S. Mayer et al.
      Pages 171-180
    4. Clinical Efficacy of Lentinan on Neoplastic Diseases

      • Tetsuo Taguchi, Hisashi Furue, Tadashi Kimura, Tatsuhei Kondo, Takao Hattori, Nobuya Ogawa
      Pages 181-187
    5. Human Macrophages May Normally be “Primed” for a Strong Oxygen Radical Response

      • Michael J. Pabst, Nancy P. Cummings, Holly B. Hedegaard, Richard B. Johnston Jr.
      Pages 215-221
  5. Synthetic Biological Response Modifiers

    1. Sodium Diethyldithiocarbamate (Imuthiol) and Cancer

      • G. Renoux, M. Renoux, E. Lemarie, M. Lavandier, J. Greco, P. Bardos et al.
      Pages 223-239

About this book

The topic of biological response modifiers has attracted the attention of many biomedical investigators, including immunologists, oncologists, pharmacologists, microbiologists, and biochemists, as well as clinical practitioners of medicine. This has occurred mainly because of the realization that the complex system of cellular and humoral interactions culminating in a productive immune response is under exquisite regulatory control for normal immune responses and that loss of control may markedly influence the capability of a host to respond in a productive manner to the numerous immunologic "insults" encountered in the environment. Furthermore, biological response modification is considered by many to be a natural offshoot of the relatively new application of "immunotherapy" to cancer. It is widely recognized that "immunotherapy" was practiced at the end of the last century and the beginning of this century when it was recognized that microbial infections were caused by distinct species of bacteria and that passive administration of serum con­ taining antibody to these microbes or their products could, in many cases, favorably influence the outcome of an infectious process.

Editors and Affiliations

  • University of South Florida, Tampa, USA

    Thomas Klein, Steven Specter, Herman Friedman, Andor Szentivanyi

Bibliographic Information

  • Book Title: Biological Response Modifiers in Human Oncology and Immunology

  • Editors: Thomas Klein, Steven Specter, Herman Friedman, Andor Szentivanyi

  • Series Title: Advances in Experimental Medicine and Biology

  • DOI: https://doi.org/10.1007/978-1-4757-1410-4

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 1983

  • Softcover ISBN: 978-1-4757-1412-8Published: 21 November 2012

  • eBook ISBN: 978-1-4757-1410-4Published: 11 November 2013

  • Series ISSN: 0065-2598

  • Series E-ISSN: 2214-8019

  • Edition Number: 1

  • Number of Pages: XIV, 320

  • Topics: Immunology

  • Industry Sectors: Biotechnology, Consumer Packaged Goods, Health & Hospitals, Pharma

Buy it now

Buying options

eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access